thoughts
Home » Archives for thoughts
Kurzweil Responds
Monday, August 23rd, 2010
Ray Kurzweil has responded to the criticism of his Singularity Summit comments on reverse-engineering the brain, a chorus to which I added my voice here . He says that he was misquoted on the timeline and on the importance of genomic data for doing it. His plan, he says, is to understand what level of complexity will be needed in order for a system to organize and adapt the way the brain does to stimuli, and the modular nature of its organization gives him hope that this can be realized: For example, the cerebellum (which has been modeled, simulated and tested) — the region responsible for part of our skill formation, like catching a fly ball — contains a module of four types of neurons
Posted in: Clinical Trials | 0 Comments »
Read the full story
Working for GSK: Slowly disengaging employees ?
Sunday, August 15th, 2010
As I reread the story on GSK and Avandia in Time magazine my thoughts turned to all the really good people who work at GSK who were torpedoed by the bad decisions of a few people. These are the people that really care about customers and patients and whose voices are muted while the media continues to talk about the problems of big pharma rather than focus on the millions of people who are living longer and better lives because of prescriptions drugs.
Posted in: DTC | 0 Comments »
Read the full story
Oil Consolidation Trend
Sunday, August 15th, 2010
Dan Dicker, senior contributor to TheStreet , reveals his thoughts on the recent consolidation in the energy sector and what stocks he’s buying.
Posted in: headlines | 0 Comments »
Read the full story
FDA WidgetGate: Implications and Recommendations
Tuesday, August 10th, 2010
Intouch Solutions’ Official POV For those of you following the commentary on FDA’s letter to Novartis regarding social sharing widgets (can we call it WidgetGate for fun?!), Intouch Solutions has some new information and recommendations to share with you. Yesterday I posted a recap , analysis, and collection of musings and opinions on the subject.
Posted in: Digital Marketing | 0 Comments »
Read the full story
Should J&J Replace The McNeil Management Team?
Friday, July 16th, 2010
The ongoing Tylenol recall scandal has been a deeply embarassing and disruptive episode for Johnson & Johnson, which has long benefited from a stellar reputation for a bevy of ubiquitous household medicines as well as its handling of the 1982 Tylenol crisis that transformed the company into a Harvard Business School model. J&J is admired in other ways.
Read the full story
The Cholesterol Debate And Journal Disclosures
Wednesday, June 30th, 2010
Earlier this week, the Archives of Internal Medicine published a few articles and editorials about statins, although one, in particular, generated some heat – a review of the controversial Jupiter study from 2008. The study, which focused on AstraZeneca’s Crestor cholesterol pill, measured levels of a protein called CRP that can indicate arteries are inflamed and point toward heart disease. The results prompted debate over the extent to which CRP should be used as a guideline for treating cholsterol and the wisdom in prescribing Crestor and other statins to people with low cholesterol.
Posted in: Pharma News | 0 Comments »
Read the full story
Peter Schiff: U.S. Is in a Depression
Saturday, June 26th, 2010
Peter Schiff, president of Euro Pacific Capital and notorious bear, reveals his thoughts on the U.S., China and investment opportunities.
Posted in: headlines | 0 Comments »
Read the full story
The Health Care Bill: A Therapeutic Rant
Monday, March 22nd, 2010
Since I’ve written occasionally about the current health care reform efforts here, I feel as if I should say something now that a bill has passed the House.
Posted in: Clinical Trials | 0 Comments »
Read the full story
Thought on compliance from reader
Friday, January 15th, 2010
I think that this is due to many factors such as 1. the vast majority of Drug raps did not get the right skills and knowledge about drugs and body system 2. Big Pharma’s prime objective was profit maximisation, which is understandable, but now is just old fashion 3.
Posted in: DTC | 0 Comments »
Read the full story
Friday ramblings
Friday, November 27th, 2009
One thing I learned while marketing supplements in the late 90’s (when the supplement market was over $1 billion) was people will take anything that promises good health in a bottle, often to compensate for bad habits.
Posted in: DTC | 0 Comments »
Read the full story
Business Week – Drug Marketing
Business Week – Pharma Marketing
Cafe Pharma
Clinical Trials.gov
FDA on Twitter
Pharma Live
Pharma Voice